Form 5 - Annual statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-006293
Filing Date
2021-02-12
Accepted
2021-02-12 16:15:50
Documents
1
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 5 SUBMISSION doc5.html 5  
1 FORM 5 SUBMISSION doc5.xml 5 6673
  Complete submission text file 0000899243-21-006293.txt   8127
Mailing Address C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104
Business Address
Kumar Neil (Reporting) CIK: 0001742485 (see all company filings)

Type: 5 | Act: 34 | File No.: 001-38959 | Film No.: 21627565

Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Issuer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations